Details of the Drug

General Information of Drug (ID: DM6S4R2)

Drug Name

DA-3031

Synonyms

Long-acting agent (neutropenia), Dong-A; PEG-GCSF (neutropenia), Dong-A; PEG-granulocyte colony stimulating factor (neutropenia),Dong-A

Indication

Disease Entry	ICD 11	Status	REF
Neutropenia	4B00.0	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

185.26

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

5

Hydrogen Bond Donor Count

0

Hydrogen Bond Acceptor Count

3

Chemical Identifiers

Formula: C10H19NO2
IUPAC Name: 2-(dimethylamino)ethyl 2-methylprop-2-enoate;ethene
Canonical SMILES: CC(=C)C(=O)OCCN(C)C.C=C
InChI: InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2
InChIKey: PNMYDOBPCBCQIA-UHFFFAOYSA-N

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Granulocyte colony-stimulating factor (CSF3)	TT5TQ2W	CSF3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Neutropenia

ICD Disease Classification

4B00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Granulocyte colony-stimulating factor (CSF3)	DTT	CSF3	7.72E-01	-1.68E-03	-0.01

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01674855) Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia. U.S. National Institutes of Health.
2	A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6.